The palatability of colloidal bulk forming agents

Area of Science:

• Gastroenterology
• Clinical Nutrition
• Consumer Science

Background:

• Dietary fiber supplements, or bulk additives, are crucial for managing various gastro-intestinal disorders.
• Patient adherence to bulk additives can be limited by palatability, impacting treatment efficacy.
• Understanding age and sex-related preferences for different bulk additives is essential for personalized therapeutic recommendations.

Purpose of the Study:

• To evaluate and compare the palatability of three commonly used bulk additives: Normacol Special, Fybogel, and Celevac Granules.
• To assess how age (under 40 vs. over 60) and sex influence the preference and palatability ratings of these additives.
• To provide insights into the therapeutic implications of bulk additive palatability in patient populations.

Main Methods:

• A palatability study involving adult volunteers across two age groups: under 40 years and over 60 years.
• Participants rated the preference and palatability of Normacol Special, Fybogel, and Celevac Granules.
• Statistical analysis was performed to identify significant differences in ratings based on the additive, age group, and sex.

Main Results:

• Women demonstrated a highly significant preference for Normacol Special over both Fybogel and Celevac Granules.
• Normacol Special received significantly higher preference and palatability scores compared to Celevac Granules overall.
• Volunteers under 40 rated Celevac Granules higher than Fybogel, while those over 60 showed the reverse preference, with sex potentially influencing the latter group's perception.

Conclusions:

• Normacol Special emerges as a highly palatable option, particularly favored by women, suggesting potential for improved adherence in clinical practice.
• Significant differences in palatability and preference exist among bulk additives, varying by age and potentially sex.
• These findings underscore the importance of considering palatability when selecting bulk additives for patients with gastro-intestinal conditions to enhance therapeutic outcomes.